Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCNBHY)

Drug Name
JNJ-42905343 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anaemia 3A90 Preclinical [1]
Iron deficiency 5B5K.0 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMCNBHY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting HIF-prolyl hydroxylase (HPH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclopirox DMN5T2A Cutaneous candidiasis 1F23.14 Approved [3]
AKB-6548 DM2EJM3 Anaemia 3A90 Phase 3 [4]
JTZ-951 DM8FSPV Anaemia 3A90 Phase 3 [5]
BAY 853934 DM407I6 Anaemia 3A90 Phase 3 [6]
FG-2216 DM7RYL4 Kidney disease GC2Z Phase 2 [7]
DS-1093 DM42KZW Anemia 3A00-3A9Z Phase 1 [8]
ZYAN1 DM796RI Anaemia 3A90 Phase 1 [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Inhibitor [2]

References

1 Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.
2 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 DOI: 10.1038/nrd4422
5 DOI: 10.1038/nrneph.2015.82
6 Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
7 Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
8 Company report (Daiichisankyo)
9 Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.